


Your weekly sampling news from our GP colleagues, Dr Debabish Kar, Dr Nick Thomas, Dr Will Elson and Dr Gavin Jamie on behalf of the Oxford RCGP RSC.

SAMPLING IS INFORMING

Our Network's Samples What your data contributed to recently

VIROLOGY



Thank you for continuing to provide virology samples from your patients.

The number of positive swabs collected in 4 weeks of from w/c on 08/08/2022 suggests that the SARS-CoV-2, RSV and Influenza viruses are the major respiratory viral infections prevalent in the community.

In the week commencing on 29th August 2022, out of 4 positive swabs, 2 were positive for SARS-CoV-2, and 1 each for influenza, and RSV. Swab collection declined in the month of August due to holiday.

This information will guide the UKHSA to decide the immunisation programme for the

coming months. We appreciate your contribution and would like to encourage you to do more swabbing.

Coding Vaccinations - How You Can Help

Group	Type of vaccine	Comment
Children between 6 months and <2 years	Egg-grown quadrivalent (inactivated)	Those with egg allergy, the cell-grown quadrivalent
Aged 2-17 years	Live attenuated vaccine Administered as a nasal spray (<i>Fluenz tetra</i> [®])	For those children for whom live attenuated vaccine is contraindicated or unsuitable, cell-grown quadrivalent or egg-grown quadrivalent (inactivated), depending on egg allergy. Children with very severely immunocompromised household contact should have cell-grown quadrivalent or egg-grown quadrivalent (inactivated) rather than the live attenuated vaccine
Adults aged 18 to 64 in a clinical risk group or other eligible groups	Cell-grown quadrivalent (inactivated) or the recombinant quadrivalent	If these options are unavailable, the egg-grown quadrivalent
Pregnant women	Cell-grown quadrivalent (inactivated) or the recombinant quadrivalent	If these options are unavailable, the egg-grown quadrivalent.
Adults aged 65 years or over	Adjuvanted egg-grown quadrivalent (inactivated) or the recombinant quadrivalent (inactivated)	If unavailable or unsuitable, offer the cell-grown quadrivalent (inactivated)

The above table provides a summary of the influenza vaccination schedule, detailing the choice of vaccines recommended by UKHSA dependent on a person's age, comorbidities and allergy status. It's based on the UKHSA's 'National flu immunisation programme 2022 to 2023 letter.'

With the roll out of the National flu immunisation programme, we'd like to remind you of the importance of coding both the brand and type of vaccine in the patient record.

This especially includes capturing any vaccinations given offsite at places such as COVID vaccination hubs and pharmacies.

Coding is key for UKHSA in understanding the uptake and effectiveness of the vaccination programme. Further details can also be found on the Guidelines 'Summary of flu immunisation guidance for England 2022–2023' webpage at:

<https://www.guidelines.co.uk/immunisation-and-vaccination/ukhsa-flu-immunisation-2022-2023-guideline/454313.article>

Book A Practice Visit!

Have you booked a practice visit yet? Maybe you'd prefer us to remotely join one of your weekly practice meetings.

Whichever way works best for you, sometimes a face-to-face chat makes all the difference. Book us in to meet your team using the button below!